Contrasting Array BioPharma (ARRY) & Its Competitors
Array BioPharma (NASDAQ: ARRY) is one of 294 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Array BioPharma to related companies based on the strength of its dividends, analyst recommendations, earnings, risk, profitability, institutional ownership and valuation.
This table compares Array BioPharma and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Array BioPharma Competitors||-5,478.57%||-421.60%||-42.15%|
Earnings and Valuation
This table compares Array BioPharma and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Array BioPharma||$43.66 million||-$100.01 million||-17.10|
|Array BioPharma Competitors||$473.33 million||$171.79 million||-7.05|
Array BioPharma’s competitors have higher revenue and earnings than Array BioPharma. Array BioPharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Array BioPharma has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Comparatively, Array BioPharma’s competitors have a beta of 6.61, suggesting that their average share price is 561% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Array BioPharma and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Array BioPharma Competitors||728||3173||11796||264||2.73|
Array BioPharma presently has a consensus price target of $13.86, suggesting a potential upside of 12.57%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 28.65%. Given Array BioPharma’s competitors higher probable upside, analysts clearly believe Array BioPharma has less favorable growth aspects than its competitors.
Insider & Institutional Ownership
87.0% of Array BioPharma shares are held by institutional investors. Comparatively, 51.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 3.2% of Array BioPharma shares are held by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Array BioPharma competitors beat Array BioPharma on 8 of the 12 factors compared.
Array BioPharma Company Profile
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.
Receive News & Ratings for Array BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array BioPharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.